Medicare FFS billing FAQs for COVID-19 testing and related services
Guidance on Medicare Fee-for-Service billing, coding, and payment policies for COVID-19 specimen collection, diagnostic and serology laboratory testing, and related billing rules during the COVID-19 Public Health Emergency (PHE); applies to Medicare providers, laboratories, and contractors.
Two new HCPCS specimen collection codes (G2023, G2024) and travel allowance rules are established for COVID-19 specimen collection during the PHE.
New laboratory test codes for COVID-19: U0001, U0002, CPT 87635, and serology CPT codes 86328 and 86769, with MACs setting interim payment rates.
Two new CPT codes (86328, 86769) were announced for COVID-19 antibody (serology) testing.
CMS created HCPCS U0003 and U0004 for COVID-19 high-throughput CDLTs and U0005 as an add-on payment when timeliness criteria are met.
Payment rates for high-throughput HCPCS codes were revised: base payment lowered to $75 and add-on $25 available starting Jan 1, 2021.
Hospitals and ASCs may use temporary expansion sites for inpatient and outpatient services during the PHE and bill Medicare as if services were at permanent hospital locations if CoPs are met.
CMS will increase the IPPS MS-DRG relative weight by 20% for discharges of patients diagnosed with COVID-19 during the PHE.
Acute care hospitals may house psychiatric or acute patients in excluded distinct part units during the emergency and should bill under the original payment system while annotating the medical record.
Patient status code '69' should be used when transferring Medicare patients to temporary care sites operated by public entities; claims with code '69' do not receive a transfer adjustment.
CMS will exclude all Parts A and B FFS payment amounts for an episode of care triggered by an inpatient service for treatment of COVID-19 from Shared Savings Program financial calculations.
Expanded list of primary care service codes for beneficiary assignment to include telehealth and technology-based services (G2010, G2012, 99421-99423, 99441-99443) for performance years during the PHE.
Application of the Extreme and Uncontrollable Circumstances Policy to shared losses: shared losses are mitigated proportionally to the duration of the PHE.
CMS will not apply the two percent sequestration reduction to ACO shared savings payments for the suspension period (claims with dates of service May 1–Dec 31, 2020).
Claims for inpatient COVID-19 treatment that occur in SNFs acting as inpatient acute care or under arrangements will trigger excluded COVID-19 episodes of care.
Episode of care length is defined in months: month of admission through month following discharge for exclusions from Shared Savings calculations.
CMS delayed multiple Medicare cost report filing deadlines and granted 60-day extensions for reporting periods ending March 1–Dec 31, 2020.
Medicare will pay for monoclonal antibody products authorized under an EUA to treat COVID-19 and for their administration under Part B consistent with Section 3713 of the CARES Act.
Allowed practitioners (NPs, PAs, CNSs) may certify, order, and recertify home health services beginning March 1, 2020; this change was made permanent by CARES Act section 3708.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.